Creative Financial Designs Inc. ADV Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Creative Financial Designs Inc. ADV boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,740 shares of the biopharmaceutical company’s stock after acquiring an additional 189 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Gilead Sciences were worth $230,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 2.6% in the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after acquiring an additional 2,910,147 shares in the last quarter. Swedbank AB acquired a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $134,489,000. International Assets Investment Management LLC raised its position in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after purchasing an additional 1,622,806 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of Gilead Sciences by 2.7% during the 1st quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after buying an additional 1,589,240 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of Gilead Sciences by 24.7% during the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after buying an additional 1,564,792 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock valued at $3,033,340 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GILD. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a research report on Monday, September 16th. Ten analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $86.85.

Gilead Sciences Trading Up 0.8 %

NASDAQ:GILD opened at $89.51 on Monday. The stock has a market cap of $111.44 billion, a price-to-earnings ratio of 109.16, a PEG ratio of 3.09 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.74. The business has a fifty day moving average of $83.79 and a 200-day moving average of $74.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Equities analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.